BRCA2 and ovarian carcinoma: Because the response to platinum-based chemotherapies or therapy with PARP inhibitors in ovarian cancer is not limited to patients with tumors harboring BRCA1 or BRCA2 mutations, we expanded the group of patients by using a genomic characterization termed BRCAness, which has very much in common with homologous recombination repair deficiency (HRD) status (61).